AGARWAL SUNIL
Known title: DirectorCIK: 0001616640
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Transaction History
| ARVN | ▲ Buy | Grant | 16,025 | $0 | 6/25/2025 | View on chart |
| ARVN | ▲ Buy | Grant | 5,899 | $0 | 5/29/2024 | View on chart |
| ARVN | ▲ Buy | Grant | 8,242 | $0 | 6/15/2023 | View on chart |
| SANA | ▼ Sell | Open Market | 1,627 | $42K | 9/16/2021 | View on chart |
| SANA | ▼ Sell | Open Market | 58,373 | $1.5M | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Arvinas Releases Q2 2026 Earnings Call Transcript
Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.
Arvinas Releases Q2 2026 Earnings Call Transcript. Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.